This pick looks looks like its setting up for a major breakout, and it`s just coming off its 52 week low. It`s time to jump right into the report. Here we go…
Our New Breakout Play is:
Website: www.nanolabs.us CTLE Is On Immediate ALERT! About Nano Labs Corp.
Nano Labs Corp. is an R&D company in nanotechnology that comprise the art and science of modifying matter at molecular and atomic scales to create what we believe are remarkable products and materials for industrial and consumer product application. Our business model is to license a range of next generation products covering many sectors of the economy, including energy and fuel, health and medicine, food and agriculture, plus Nano products and materials with the potential for broad-based industrial and consumer goods applications.
I know by now most of you have heard of nanotechnology It`s a fascinating technology that`s piqued the interest of many people.
It`s attracting a lot of investors too.
Nanotechnology is all about building materials — really, really tiny ones. We`re talking molecules involved in the design and build of new materials at the molecular level to improve performance.
At the nanometer-size scale, materials take on dramatically new properties.
Nanotech is the new revolution like digital or the Internet, nanotechnology has not lacked for endorsements.
CTLE is a hatchling in the nanotechnology research and development field.
And from the looks of it CTLE is banking on a new nano coating can serve as an insulation to reduce energy costs up to 40%. The product is currently named “NC2012.” (read more) In 2014, the global paints & coatings market is forecast to have a value of $105.8 billion, an increase of 15.4% since 2009.
Now that CTLE was awarded a provisional patent number for a next-generation nano thermal insulation coating — news that could carve a path in the industry to commercialize their innovative nano thermal insulation product. (read more) Keep in mind this technology is relatively young, and it`s early to tell which companies will dominate but if CTLE wins this patent its stock price could skyrocket.
With a variety of potential applications, Nanotechnology is a key technology for the future.
The USA has invested 3.7 billion dollars along with the European Union who has invested 1.2 billion and Japan with 750 million dollars in the game. (read more) Nantechnology is on the go (WSJ) and CTLE is the new kid on the block and it looks like it could be setting up for a major breakout! Start Your Research Now! As always we encourage subscribers to do their own due diligence and visit the company website: www.nanolabs.us Happy Trading!! Your OTCtipReporter Team DONT MISS ANOTHER HOT OPPORTUNITY TO MAKE HUGE PROFITS! Help Spread the word about OTCtipReporter! You can call us toll free at: 1-800-850-9305 Offices are open Monday through Friday, 9:30 am to 4:00 pm EST Email: office@OTCtipReporter.com www.OTCtipReporter.com Investor Awareness and IR Services If you are interested in our Investor Awareness and IR Services contact us at 1-800-850-9305 or email us at office@OTCtipReporter.com GENERAL NOTICE AND DISCLAIMER – PLEASE READ CAREFULLY The companies that are discussed on OTCtipReporter.com have not approved the statements made. This opinion contains forward-looking statements that involve risks and uncertainties. A company`s actual results could differ materially from those described in any forward-looking statements or announcements discussed herein. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. OTCtipReporter.com is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Nor are any of its officers, affiliates, or employees. Please consult a broker before purchasing or selling any securities viewed on OTCtipReporter.com or mentioned herein.
Affiliates, officers, directors and employees of OTCtipReporter.com may have also bought or may buy shares of companies mentioned herein and may profit in the event those shares rise in value.
OTCtipReporter.com wi ll not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make their own decision based on his or her judgment of the market. This advertisement is not a solicitation or recommendation to buy, sell or hold securities and does not provide an analysis of the financial position of the company. We recommend you use the information found in this advertisement as an initial starting point for conducting your own research on the advertised company in order to determine your own personal opinion of the company before investing. All statements and opinions contained in this advertisement are the sole opinion of the authors and are subject to change without notice. We are not liable for any investment decisions by our readers. Readers should independently investigate and fully understand all risks before investing. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser or broker prior to completing any such purchase or sale decision. We are not registered investment advisers, or broker-dealers, or members of any financial regulatory bodies. Furthermore, our associates and/or employees and/or principals may have stock positions in advertised companies purchased in the open market or in private transactions.
These positions may be liquidated, without prior notification, even after we have made positive comments regarding the advertised company. The receipt of this information constitutes your acceptance of these terms and conditions. Reading this advertisement shall not create under any circumstances an offer to buy or sell stock in any company advertised. Nor shall it create any principal-agent relationship between the reader and us. Void where prohibited. Information within this advertisement contains “forward looking” statements within the meaning of Section-27(a) of the U.S. Securities Act-of-1933 and Section 21(e) of t he U.S.
Securities Exchange Act-of -934. Neither OTCtipReporter.com, its officers, affiliates, or employees is a broker-dealer. The information on OTCtipReporter.com, including the opinions expressed and the statements made within, is for informational and advertising purposes only and should not be construed as investment-advice, and does not constitute an offer to sell any securities, nor is it to be construed as a solicitation to purchase any securities in any state or other jurisdiction where the offer or sale is not permitted. The information to prepare this report is believed to be from reliable sources, but no representation is made as to the accuracy or completeness of such information. Investment in securities carries a high degree of risk and involves risks and uncertainties, which may result in investors losing all of their invested capital. Past performance does not guarantee future results. The information contained herein contains “forward-looking statemen ts,” within the meaning of Section-27A of the Securities Act-of-1933 and Section 21E of the Securities Exchange Act-of-1934.
Forward-looking statements are based upon expectations, estimates and projections at the time the statements are made and involve risks and uncertainties that could cause actual events to differ materially from those anticipated. Forward-looking statements may be identified through the use of words such as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should, or might occur. Any statements that express or involve predictions, expectations, beliefs, plans, projections, objectives, goals or future events or performance may be forward-looking statements. Factors that could cause actual results to differ materially include but are not limited to adverse economic conditions, intense competition, lack of meaningful research results, inadequate capital, termination of contracts or agreements, adv erse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other key personnel, and other risks detailed in the reports filed with the Securities and Exchange Commission by the companies who are mentioned in this periodical. Readers should consult with their own professional investment, tax and portfolio advisors before making any investment decision and should independently verify all information herein.
More complete information about any of the companies mentioned in this periodical is available from the website of the Securities and Exchange Commission, at sec.gov, and copies of their filings may be read without charge and copies obtained at prescribed rates from the public reference facilities of the Commission, at 450 Fifth Street, NW, Washington, DC 20549.
Buying and Selling of Shares OTCtipReporter.com intends to sell its shares. OTCtipReporter.com may sell its shares for less than target prices given in opinions.
OTCtipReporter.com affiliates, officers, directors and employees may have also bought or may buy the shares discussed in this report and may profit in the event those shares rise in value.
OTCtipReporter.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. There are risks involved Always remember that OTCtipReporter.com are not analysts and investing in securities such as the ones listed within are for high risk tolerant individuals only and not the general public. Whether you are an experienced investor or not you should always consult with a broker before purchasing or selling any securities viewed on OTCtipReporter.com. If at any time you wish to be removed from our list simply